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Abstract
Background: Interferon-γ (IFN-γ, a type II IFN) is present in the central nervous system (CNS) under various
conditions. Evidence is emerging that, in addition to its immunological role, IFN-γ modulates neuronal morphology,
function, and development in several brain regions. Previously, we have shown that raising levels of IFN-β (a type I
IFN) lead to increased neuronal excitability of neocortical layer 5 pyramidal neurons. Because of shared non-
canonical signaling pathways of both cytokines, we hypothesized a similar neocortical role of acutely applied IFN-γ.
Methods: We used semi-quantitative RT-PCR, immunoblotting, and immunohistochemistry to analyze neuronal
expression of IFN-γ receptors and performed whole-cell patch-clamp recordings in layer 5 pyramidal neurons to
investigate sub- and suprathreshold excitability, properties of hyperpolarization-activated cyclic nucleotide-gated
current (Ih), and inhibitory neurotransmission under the influence of acutely applied IFN-γ.
Results: We show that IFN-γ receptors are present in the membrane of rat’s neocortical layer 5 pyramidal neurons.
As expected from this and the putative overlap in IFN type I and II alternative signaling pathways, IFN-γ diminished
Ih, mirroring the effect of type I IFNs, suggesting a likewise activation of protein kinase C (PKC). In contrast, IFN-γ did
neither alter subthreshold nor suprathreshold neuronal excitability, pointing to augmented inhibitory transmission
by IFN-γ. Indeed, IFN-γ increased electrically evoked inhibitory postsynaptic currents (IPSCs) on neocortical layer 5
pyramidal neurons. Furthermore, amplitudes of spontaneous IPSCs and miniature IPSCs were elevated by IFN-γ,
whereas their frequency remained unchanged.
Conclusions: The expression of IFN-γ receptors on layer 5 neocortical pyramidal neurons together with the acute
augmentation of inhibition in the neocortex by direct application of IFN-γ highlights an additional interaction
between the CNS and immune system. Our results strengthen our understanding of the role of IFN-γ in neocortical
neurotransmission and emphasize its impact beyond its immunological properties, particularly in the pathogenesis
of neuropsychiatric disorders.
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Background
Interferons (IFN) are antiviral cytokines known for their
multifaceted influence on the immune response. Based
on their amino acid sequence, three types of IFNs are
distinguished: IFN I to III. All of them possess specific
receptors and signaling cascades [1].
IFN-γ is the only member of type II IFNs. It plays an
important role in innate and adaptive immune response
and induces antitumor mechanisms [2]. In addition to
peripheral immune cells, central nervous system (CNS)
cells such as microglia, astrocytes, dorsal root ganglion
neurons, and cerebrovascular endothelial cells produce
IFN-γ [3] under different conditions. Consecutively, IFN-γ
concentration in the brain is elevated in certain patholo-
gies, including multiple sclerosis [4], cerebral ischemia [5],
and neurotrauma [6]. The concentration of IFNs in the
brain is also elevated in cerebral and systemic viral infec-
tion [7, 8].
IFNs influence the CNS function in multiple ways [3, 9].
IFN-γ is involved in dendritic remodeling [10] and synaptic
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: ulf.strauss@charite.de
1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute
of Cell Biology & Neurobiology, Charitéplatz 1, 10117 Berlin, Germany
Full list of author information is available at the end of the article
Janach et al. Journal of Neuroinflammation           (2020) 17:69 
https://doi.org/10.1186/s12974-020-1722-y
stripping by microglia [11] as well as influences the prolif-
eration of neuronal precursor cells [12]. Dysregulation of
IFN-γ production might be involved in the pathogenesis of
neuropsychiatric disorders, such as depression [13] and
schizophrenia [14].
The proinflammatory effects of IFN-γ are canonically
mediated by binding to the multimeric IFN-γ receptor
(IFN-γR), subsequently activating the Janus kinase/signal
transducer and activator of transcription (JAK-STAT)
pathway. Ultimately, STAT1 phosphorylation leads to
the formation of STAT1-STAT1 homodimers, which
regulate over 200 genes via binding of the γ-IFN activa-
tion site [15, 16]. Apart from that, IFN-γ activates alter-
native pathways, involving phosphatidylinositol 3-kinase
(PI3-kinase) and various isozymes of protein kinase C
(PKC) [17, 18]. These latter alternative pathways are also
engaged in type I IFN signaling. Notably, there is evi-
dence for activation of similar PKCs by both type I and
type II IFNs in several non-neuronal cells [18, 19]. Previ-
ously, we have shown type I IFN-induced modifications of
neuronal function of layer 2/3 and layer 5 pyramidal neu-
rons that were PKC mediated. In particular, type I IFNs in-
duced an increase in sub- and suprathreshold excitability
[20, 21] due to PKC-mediated concerted action on multiple
ion channels, including a decrease in hyperpolarization-
activated cyclic nucleotide-gated cation (HCN) channel-
mediated hyperpolarization-activated current (Ih) [20, 22].
This neuromodulatory effect of type I IFNs implies a role
in the altered neuronal states during inflammation and
might cause some of the side effects of IFN therapy. To
what extent this can be generalized to type II IFN is cur-
rently unknown. So far, information on IFN-γ influence on
intrinsic neuronal properties is sparse. Synaptic effects have
been reported only for long-term application and are
controversial [23–25]. Nevertheless, given the overlapping
signaling pathways of type I and II IFNs, we hypothesize
comparable neuromodulatory effects of these IFNs. Conse-
quently, we here establish the presence of type II IFN re-
ceptor on layer 5 pyramidal neurons in the rat neocortex
and analyze the immediate consequences of IFN-γ applica-
tion on neuronal excitability, ion channel function, and syn-
aptic transmission.
Methods
Animals and slice preparation
Male Wistar rats obtained from Janvier labs (Saint-Berthe-
vin, France) or from the Charité central animal facility
FEM (Berlin, Germany) were kept under standard labora-
tory specific-pathogen-free (SPF) conditions. All proce-
dures were performed in agreement with the European
Communities Council Directive of September 22, 2010
(2010/63/EU), and carried out in accordance to state of
Berlin rules (registration no. T0212/14). Immunohisto-
chemical experiments as well as RNA extraction were
done in postnatal day (P)20 and P60 rats. Acute coronal
brain slices for electrophysiological recordings were pre-
pared from P10 to P84 rats mainly according to Stadler
et al. [22]. Differing from the procedure used in that publi-
cation slices were cut in 2 °C cold carbogenated (95% O2,
5% CO2), sucrose artificial cerebrospinal fluid (sACSF)
containing (in mM) 85 NaCl, 2.5 KCl, 1 NaH2PO4, 7
MgCl2, 26 NaHCO3, 50 sucrose, 10 D(+)-glucose (all from
Carl Roth, Karlsruhe, Germany), and 0.5 CaCl2 (Merck,
Darmstadt, Germany). Slices were allowed to recover in
33 ± 1 °C warm sACSF for 30min and subsequently stored
at room temperature (RT) in a solution that contained (in
mM) 92 NaCl, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 25
D(+)-glucose (Carl Roth), 5 sodium ascorbate, 20 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES),
3 sodium pyruvate (Sigma-Aldrich, Steinheim, Germany),
2 thiourea (VWR Chemicals, Radnor, PA, USA), 2 MgSO4,
and 2 CaCl2 (Merck).
RNA extraction, cDNA synthesis and ifngr1 amplification
Neocortex was harvested from three male Wistar rats
and homogenized in TRIzol (Invitrogen, Carlsbad,
CA, USA) reagent. Total RNA was extracted using
the TRIzol reagent according to the manufacturer’s
protocol (Invitrogen). The concentration and purity of
the isolated total RNA were determined by spectro-
photometric analysis of 5 μg total RNA using the
High-Capacity cDNA Archive Kit (Applied Biosys-
tems, Carlsbad, CA, USA) according to the manufac-
turer’s protocol. Control reaction was performed
without MultiScribe reverse transcriptase. The quality
of the amplified cDNA (with and without MultiScribe
reverse transcriptase) was controlled by β-actin PCR.
For amplification of ifngr1 cDNA, the primers ifngr1
5′ (5′-aag ctt gct ctc tgt ggt aaa aaa tgc-3′) spanning
bases 921–941, and ifngr1 3′ (5′-ctg cag tta gga cag
ttc ctg ggt atc-3′), complementary to bases 1453–
1473 with an amplification length from 552 bp of the
ifngr1 cDNA (GenBank accession no. NM_053783),
were used. Primers for the amplification of the con-
trol gene β-actin were as follows: β-actin 5′-primer
(5′-cac cac agc tga gag gga aat cgt gcg tga-3′) span-
ning the bases 681–710 and β-actin 3′-primer (5′-att
tgc ggt gca cga tgg agg ggc cgg act-3′) complementary to
bases 1169–1198 with an amplificate length of 520 bp for
β-actin cDNA (GenBank accession number NM_
031144.3). Due to intron inclusion, the same primers re-
sult in an amplificate length of 730 bp when genomic
DNA serves as template, thus this primer combination de-
tects possible contamination with genomic sequences.
PCR was performed in 25-μl final volume containing
1-mM deoxynucleotide triphosphates (dNTPs) (Bioline,
London, UK), 2.5 units GoTaq Polymerase (Promega,
Fitchburg, WI, USA), 2.5 μl 10× buffer including 2.5M
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MgCl2 (Promega), 10 μM of each primer, and 1 μl of
each cDNA for all molecules analyzed using a thermal
cycler (Duo Cycler Software version 2.3.0.0, VWR, Rad-
nor, PA, USA). For ifngr1 and β-actin, the cycle program
was 2 min 95 °C, 30 × [95 °C, 30 s; 63 °C, 30 s; 72 °C, 60 s],
and 5 min 72 °C. The ifngr1 fragment was cloned into
the TA-TOPO vector (Invitrogen) and sequence of
ifngr1 cDNA confirmed.
Immunoblotting
For Western blot analysis from cytosol and membrane
protein, the extract of the neocortex from individual P20
or P60 rats was subjected to 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions and then blotted to a nitrocellulose
membrane (Whatman, Dassel, Germany) by semi-dry
protein transfer. Blots were blocked for 1 h at RT in 5%
skimmed milk (Sigma-Aldrich)/0.1% Tween/1× PBS and
then incubated overnight at 4 °C with a 1:1000 dilution
of rabbit-anti-IFN-γ-Rα (C-20), sc-700 (Santa Cruz Bio-
technology Inc., Dallas, TX, USA), and 1:10.000 dilution
of mouse-anti-β-actin, AC-74 (Sigma-Aldrich). After
three washes in 1× PBST, the membranes were incubated
with a 1:5000 dilution of an anti-mouse Alexa Fluor 488
or 1:10.000 anti-rabbit horseradish peroxidase-labeled
antibody (GE Healthcare, Chicago, IL, USA) for 1.5 h at
RT. Immunoreactive bands were detected using ECL
Western blotting detection reagents (GE Healthcare). As
internal loading control β-actin expression was used
throughout, chemiluminescence and fluorescence images
were taken using the BioRad ChemiDoc MP System (Bio-
Rad Laboratories, Hercules, CA, USA).
Immunohistochemistry
Male Wistar rats were deeply anesthetized with 1.2 to
1.5 ml of a cocktail of 25 mg/ml ketamine, 1.2 mg/ml
xylazine, and 0.25 mg/ml acepromazine and transcar-
dially perfused with saline (0.9% NaCl), followed by 4%
paraformaldehyde (PFA) in 0.1M phosphate buffer (PB)
(2% di-sodium hydrogen phosphate heptahydrate and
0.2% sodium di-hydrogen phosphate monohydrat (both
from Carl Roth)). The brain was removed and post-fixed
in the PFA/PB fixative solution overnight at 4 °C. Next,
coronal sections (50 μm) of the forebrain were cut with
a vibratome (Microm HM 650 V, Thermo Fisher Scien-
tific, Waltham, MA, USA), washed in 0.1M PB, and
blocked with 0.1MPB including 1% BSA (Serva Electro-
phoresis GmbH, Heidelberg, Germany) and 0.1% TritonX-
100 (Sigma-Aldrich) overnight at 4 °C. Sections were subse-
quently incubated with anti-IFN-γ-Rα (C-20): sc-700 (1:
500) (Santa Cruz Biotechnology Inc.) and anti-MAP2 (1:
250) (Sigma-Aldrich) in blocking solution (0.1M PB includ-
ing 1% BSA) overnight at 4 °C. After several washes in 0.1
MPB, the sections were incubated with the second
antibodies: Alexa 488-labeled goat anti-rabbit or Alexa 568-
labeled goat anti-mouse (both 1:500) (Molecular Probes
Inc., Eugene, OR, USA) in blocking solution for 2 h at RT.
Sections were washed in 0.1MPB before mounting. Con-
focal micrographs of fluorescent specimens were taken
using an upright Leica TCS SL SP2 confocal microscope
(Leica Microsystems, Wetzlar, Germany). Scanning was
performed using an HCX PL APO CS 63x/NA1.4 oil ob-
jective at a resolution of 512 × 512 pixels in z-stack steps of
0.1 μm. Different wavelengths of fluorescence channels
were imaged separately to rule out spill over. Images are
presented as single scans and projections of stacks (27–52
sections). Images were processed in brightness and contrast
using Fiji (https://fiji.sc/; RRID: SCR_002285, [26]).
Interferon
For all experiments, we used Chinese hamster ovary
(CHO) derived recombinant IFN-γ (U-Cytech, Utrecht,
Netherlands) in a final concentration of 1000 IUml−1.
The lyophilized product was reconstituted in sterile
double-distilled water, and small aliquots were stored at
− 20 °C.
Patch clamp recordings
Individual slices were transferred to a submerged re-
cording chamber containing carbogenated (95% O2, 5%
CO2), artificial cerebrospinal fluid (ACSF) composed of
(in mM) 119 NaCl, 2.5 KCl, 1 NaH2PO4, 1.3 MgCl2, 26
NaHCO3, 10 D(+)-glucose (Carl Roth), and 2.5 CaCl2
(Merck).
Somatic whole-cell recordings were performed in visu-
ally identified layer 5 pyramidal neurons (mean capaci-
tance 220.8 ± 19.7 pF, n = 58). The pipette solution for
voltage clamp Ih recordings contained (in mM) 120
KMeSO4 (ICN Biomedicals, Eschwege, Germany), 20
KCl, 4 NaCl, 14 Na-phosphocreatine (Carl Roth), 0.5
ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraa-
cetic acid (EGTA), 10 HEPES, 4Mg2+-ATP, and 0.3
GTP with 0.1 cAMP (Sigma-Aldrich) (pH 7.25, 288
mOsm). Ih was pharmacologically isolated [27] by modi-
fying the ACSF (in mM, 10 KCl and NaH2PO4 omitted)
and blocking confounding currents by 400 μm Ba2+, 1
mM Ni2+ (Merck), 1 μm tetrodotoxin (TTX), 10 μm 6-
cyano-7-nitroquinoxaline-2,3-dione (CNQX), 25 μm D-
(-)-2-amino-5-phosphonopentanoic acid (DAP-5), 10 μm
bicuculline (Tocris, Bristol, UK), 5 mM 4-aminopyridine
(4-AP), and 10 mM tetraethylammonium (TEA) (Sigma-
Aldrich).
All inhibitory currents were recorded in the presence
of 20 μM CNQX and 25 μM DAP-5 (both from Tocris)
to block ionotropic glutamate receptors. Evoked inhibi-
tory postsynaptic currents (eIPSCs) were elicited at a
somatic holding potential of − 70 mV by square pulses
(100 μs, 5–40 μA) every 30 s via a glass electrode filled
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with ACSF positioned approx. 100 μm laterally and 150 μm
apically from the soma, using a stimulus isolator (ISO-Flex,
Science Products, Hofheim, Germany). IFN-γ was applied
when eIPSC amplitudes remained comparable for at least
10min. Pipette solution for eIPSC and sIPSC recordings
contained (in mM) 140 CsCl (Sigma-Aldrich), 4 NaCl, 1
MgCl2 (Carl Roth), 10 HEPES, 0.1 EGTA, 0.3 GTP, 2Mg
2+-
ATP, and 5 QX-314 (Sigma-Aldrich) [pH 7.2, 292 mOsm].
Spontaneous IPSCs (sIPSCs) and miniature IPSCs (mIPSCs)
were recorded at a holding potential of − 60mV. For mIPSC
recordings, 1 μM TTX was additionally present in the ACSF
and the pipette solution contained (in mM) 130 KCl, 10 Na-
phosphocreatine, 1 MgCl2 (Carl Roth), 1 CaCl2 (Merck), 11
EGTA, 10 HEPES, 2Mg2+-ATP, and 0.3 GTP (Sigma-Al-
drich) [pH 7.2, 290 mOsm]. IPSCs were gathered from 1 to
3min before and after application of IFN-γ as negative de-
flections > 5 × RMS noise.
Electrophysiological characterization of neurons was
hampered in experiments on inhibition due to the spe-
cific intracellular solutions. Therefore, biocytin (0.1%,
Invitrogen) filling and post hoc staining was applied to a
subset (n = 15) to monitor accuracy of visual selection.
For morphological identification, slices were fixed in
0.4% paraformaldehyde in 0.1% PB at 4 °C for 1 h. Prior
to visualization of recorded neurons, slices were washed
in PB and saline-buffered PB (PBS, 0.9% NaCl) subse-
quently blocked in PBS containing 10% normal goat
serum, 0.3% TritonX-100, and 0.05% NaN3 for at least 1 h.
Slices were then incubated with fluorescent-conjugated
streptavidin (Alexa Fluor-647, 1:1000, Invitrogen), in a
PBS solution containing 3% normal goat serum, 0.1%
TritonX-100, and 0.05% NaN3 for 24 h at 4 °C. Before
slices were mounted for imaging, they have been washed
in PBS and desalted in PB. Recorded neurons were imaged
and identified using a laser scanning confocal microscope
(FV1000, Olympus, Japan) and sample reconstruction was
done using Fiji software package [26] and neuTube [28].
For current clamp measurements, pipette solution con-
tained (in mM) 120 potassium gluconate, 10 KCl, 10 Na-
phosphocreatine, 1 MgCl2 (Carl Roth), 1 CaCl2 (Merck),
11 EGTA, 10 HEPES, 2Mg2+-ATP, and 0.3 GTP (Sigma-
Aldrich) (pH 7.2, 290mOsm). Pipettes had a tip resistance
between 2 and 5MΩ.
Data were recorded with an EPC-10 USB double amp-
lifier (HEKA, Lambrecht, Germany), digitized (minimum
of 10 kHz, after Bessel filtering at 2.5 kHz), and stored
using the PatchMaster software (HEKA).
A maximal series resistance of 20MΩ with changes
< 25% during recordings was tolerated. A fast (pipette)
capacitive transient (τ < 1.5 μs, 6–13 pF) was compen-
sated. Input resistance was calculated with a linear fit
of the current clamp generated I-V plot in close vicinity
of the resting potential (± 50 pA). Intersection of the
linear regression of the F-I relationship (estimated in
the linear range) and abscissa roughly approximated
the rheobase.
Statistical analysis
Data was tested for normal distribution using the
Shapiro-Wilk test. In case of normal distribution, paired
Student’s t tests were used to test for significant differ-
ences. In case of significant deviation from normal distri-
bution (P > 0.05), the non-parametric Wilcoxon signed-
rank test was used. Kinetic analysis of the 10% biggest
amplitudes of the mIPSCs was fitted by a single expo-
nential equation (y = y0 + A1(e − x/τ1)), and the cumula-
tive frequency of mIPSCs and sIPSCs was analyzed using
a two-sample Kolmogorov-Smirnov test. Data are pre-
sented as mean ± standard error of the mean (SEM). Re-
sults with P < 0.05 were regarded as statistically significant.
Statistics were performed with Origin2019 (OriginLab,
Northhampton, MA, USA) or Statview v.457 (Abacus Con-
cepts Inc., CA, USA).
Results
IFN-γ receptor (IFN-γR) is expressed in neocortical layer 5
pyramidal neurons
IFN-γR expression has been confirmed for several brain
regions [24, 29]. Information on the cellular localization
of the receptor, however, is currently missing for many
neuron types. Here we provide evidence for the expres-
sion of IFN-γR on neocortical layer 5 neurons. Using
semi-quantitative RT-PCR analysis, we first assessed the
transcriptional level and demonstrated that mRNA of
the receptor is expressed in late juvenile and adult cortical
tissue (Fig. 1a, b, left). Subsequent Western blot studies de-
tected posttranslational expression of the ligand binding
receptor α chain (IFN-γRα, also known as IFNGR1 or
CD119) only in the membrane fractions derived from neo-
cortical tissue (Fig. 1a, b, right). This suggests that inter-
feron receptors are present on membranes of neocortical
cells as astrocytes, microglia, neurons, or cerebrovascular
endothelial cells. To visualize the local expression of the re-
ceptor, we used immunohistochemical staining with anti-
IFN-γRα and anti-MAP2 in neocortical layer 5 of brain
slices. IFN-γRα was clearly detectable in neuronal somata
and weakly in dendrites, as shown by co-localization with
the neuronal marker MAP2 (Fig. 1c, d). The presence of
IFN-γRs in the cell membrane suggested the existence of
the entire heteromeric IFN-γR at the surface of, and there-
fore, an influence of IFN-γ on neocortical layer 5 pyramidal
neurons.
IFN-γ application leaves neuronal excitability of layer 5
pyramidal neurons unchanged
Crosstalk for type I and type II IFNs has not only been
shown for the canonical pathways [31], but also for the
activation of PKC [15, 19]. We have shown previously
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Fig. 1 Endogenous IFNγRα is expressed in neocortical layer 5 neurons of late juvenile and adult rats. a, b Semi-quantitative RT-PCR analysis and
Western blots were performed on neocortical tissue of P20 (a, late juvenile) and P60 rats (b, adult). Note that PCR analysis and Western blot were
done on the same animal, i.e., neocortical tissue of one hemisphere was used for PCR, while the correspondent neocortex was used for Western
blotting. The results shown are representative for three independent experiments, respectively. Left panels, semi-quantitative RT-PCR analysis of
ifngr1 mRNA, showing transcriptional gene expression of IFN-γR in the neocortex. The size of the expected fragments corresponds to the
expected size (552 base pairs for ifngr1 fragment). Loading control, β-actin cDNA fragments (520 base pairs). Right panels, Western blot of
neocortical tissue from the same animal. Detected protein bands range from 45 to 100 kDa (96 kDa predicted by the primary structure of IFNGR1).
Similar protein species were previously found to specifically bind IFN-γ [30]. Therefore, we regard the bands to be either full-length or fragmented
IFN-γRα that might be post-translationally modified. Alexa 488-labeled β-actin was used as loading control. For estimation of the molecular
weight, the commercial weight markers Hyperladder I (for PCR; Bioline) and BlueStar Prestained Protein Marker (for Western blot; Nippon
Genetics, Tokyo, Japan) were used. c, d Examples of immunohistochemical co-staining of neocortical tissue in layer 5 with anti-IFNγ-Rα (1:500)
and anti-MAP2 (neuronal marker) (1:250) in P20 (c) and P60 (d) rats. Left, single scans for accurate z-localization of Alexa 488-labeled IFNγ
receptors α and Alexa 568-labeled MAP2. Right, summations of z-stacks consist of 26 (c) or 52 single sections (d)
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that type I IFNs boost suprathreshold excitability via
activation of PKC [21]. To elucidate whether IFN-γ
similarly triggers a change in excitability, we investi-
gated the firing behavior of layer 5 pyramidal neurons
before and 20 min after direct application of IFN-γ. In
contrast to type I IFNs that augment the suprathres-
hold excitability of about 65% of layer 2/3 and layer 5
pyramidal neurons [20], IFN-γ did not change the
suprathreshold excitability in layer 5 pyramidal neurons
as reflected in similar F-I slope (ctrl 114 ± 11 Hz/nA vs.
IFN-γ 96 ± 14 Hz/nA; n = 9; P = 0.23, paired t test) and
rheobase, i.e., the minimal current amplitude for action
potential induction (ctrl 194 ± 27.7 pA vs. IFN-γ 225 ±
32 pA; n = 9, P = 0.40, paired t test) (Fig. 2a, c). The
resting membrane potential (Vm-ctrl = − 68 ± 0.1 mV vs.
Vm-IFN-γ = − 67 ± 0.2 mV; n = 9, P = 0.16, Wilcoxon
signed-rank test) remained constant during the experi-
ments. Furthermore, the input resistance (Rin) as a
measure of subthreshold excitability also remained un-
changed upon IFN-γ application (Rin-ctrl 55.7 ± 0.8 MΩ
vs. Rin-IFN-γ 59.7 ± 0.9 MΩ; n = 9, P = 0.46, paired t test;
Fig. 2b). This precludes the possibility that we might
have recorded mainly from neurons that were margin-
ally or not affected in their suprathreshold response.
In summary, the lack of effect of IFN-γ on sub- and
suprathreshold excitability indicates either a failed
crosstalk or additional interfering mechanisms.
IFN-γ reduces Ih amplitude and slows its kinetics
Given the well-established PKC activation by IFN-γ
[17, 18], the lack of a neuromodulatory effect might
be due to a failed PKC-mediated channel modulation
upon IFN-γ. As we have robust information on the
effects of type I IFNs on Ih [22] mediated by the PKC
pathway [21], we next analyzed the influence of IFN-
γ on Ih.
Acute application of IFN-γ (1000 IUml−1) led to a re-
duction of Ih amplitude by about 25% from Ih-ctrl =
881.4 ± 136.8 pA to Ih-IFN-γ = 640.7 ± 110.2 pA (n = 16;
P < 0.001, Wilcoxon signed-rank test). This attenuation
occurred in all investigated neurons within 10min of
application (Fig. 3a, b). The reduction of Ih amplitude was
associated with a depolarization of the midpoint of activa-
tion V1/2 (Fig. 3c; V1/2-ctrl = − 89.0 ± 1.0mV to V1/2-IFN-γ =
− 86.2 ± 1.2mV; n = 16, P < 0.05, paired t test). This shift
in V1/2 cannot account for the reduction of the peak amp-
litude and argues against a classical rundown. In addition,
we estimated Ih amplitudes at full activation under both
conditions.
In our previous study, we observed a distinct effect of
type I IFNs on Ih kinetics [22]. The same effect appeared
upon application of IFN-γ: the current onset was faster,
i.e., the fast time constant τfast increased from τfast-ctrl =
60.9 ± 8.3 ms to τfast-IFN-γ = 82.8 ± 13.9 ms (n = 16; P <
0.01, Wilcoxon signed-rank test, Fig. 3d), whereas the
slow time constant τslow remained unchanged (τslow-ctrl =
560.4 ± 122.7 ms vs. τslow-IFN-γ = 1096.0 ± 403.8 ms; n =
16, P = 0.27, Wilcoxon signed-rank test). Besides the
activation kinetics, also the deactivation slowed down
(τctrl = 194.8 ms ± 28.7 ms to τIFN-γ = 246.0 ms ± 25.7 ms;
n = 16, P < 0.01, Wilcoxon signed-rank test, Fig. 3d). The
modulation of Ih by IFN-γ corresponds qualitatively and
quantitatively to previously observed effects of type I
IFNs on Ih [22] that were due to activation of PKC [21].
These data establish a link between IFN-γ, PKC activa-
tion, and attenuated Ih, rendering a concerted action of
IFN-γ on several ionic channels likely.
Fig. 2 IFN-γ does not acutely alter excitability of neocortical layer 5
neurons. Direct application of 1000 IU ml−1 IFN-γ for 20 min did
neither change suprathreshold nor subthreshold excitability. a
Example traces of a layer 5 pyramidal neuron before (black) and
upon IFN-γ application (red) showing comparable firing and
subthreshold behavior. Traces resemble voltage responses to
rectangular current injections of − 300, − 50, 50, and 250 pA,
respectively. The dotted gray line indicates a potential of − 72 mV. b
Input resistance, as a measure of subthreshold excitability, remained
unchanged upon the application of IFN-γ. c Action potential
frequency of an example neuron plotted as a function of the input
current (left). Population data reveal that neither F-I slope (middle)
nor rheobase (right) was affected by IFN-γ. As two neurons showed
overlapping F-I slopes, the corresponding dots in the line series are
slightly dispersed from each other. Lines represent the fit through
the linear part of the curve. Rs remained constant (Rs-ctrl = 7.6 ± 0.6
MΩ vs. Rs-IFN-γ = 7.3 ± 0.5 MΩ, n = 9; P = 0.23, paired t test)
throughout the experiments. The average age of animals used for
these current clamp experiments was P30 ± 2.8. In this and all
following figures, columns indicate mean and open circles in line
series resemble individual values before (black) and after (red)
application of IFN-γ; *P < 0.05, **P < 0.01, ***P < 0.001
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Inhibitory synaptic transmission is increased in amplitude
by elevated IFN-γ levels
These conflicting results—the lack of change in neuronal
excitability on one, the overlap between IFN-γ and type
I IFNs regarding channel modulation on the other
hand—prompted us to consider other putative IFN-γ
targets. Taking the role of neuronal inhibition to restrict
neocortical excitability [32–34] into account, we hypoth-
esized that IFN-γ augments GABAergic inhibition.
To investigate a possible impact of IFN-γ on GABAergic
transmission, we evoked IPSCs (eIPSCs), before and 20 to
40min after application of IFN-γ using electrical stimulation.
IFN-γ increased the maximum amplitude of eIPSCs in the
presence of glutamate receptor blockers by 48% (ctrl 605 ±
160 pA to IFN-γ 889 ± 263 pA; n= 6, P < 0.05, Wilcoxon
signed-rank test; Fig. 4b, c). The area under the curve (AUC)
that represents the total membrane charge transfer showed a
trend towards increase (ctrl 3.33 ± 1.89 nA vs. IFN-γ 4.40 ±
2.48 nA; n= 6, P= 0.21, Wilcoxon signed-rank test), maybe
due to bulk-induced increased uptake.
To address GABAergic transmission on the level of sin-
gle synapses, we measured spontaneous IPSCs (sIPSCs) 20
to 30min after application of IFN-γ. The amplitude of
sIPSCs increased by 14.6% (from ctrl 62.4 ± 8.7 pA to IFN-
γ 69.5 ± 8.8 pA; n = 9, P < 0.05, paired t test) while the fre-
quency of sIPSCs remained unchanged (ctrl 13.7 ± 3.0
events s−1 vs. IFN-γ 15.7 ± 4.0 events s−1; n = 9, P = 0.42,
paired t test, Fig. 5a–c). Comparison of the largest (≥ 60
pA) sIPSCs that are putatively action potential driven
showed comparable amplitudes (ctrl 99.0 ± 7.8 pA vs.
IFN-γ 100.9 ± 6.8 pA; n = 9, P = 0.16, paired t test) or fre-
quencies (ctrl 4.0 ± 1.1 events s−1 vs. IFN-γ 5.8 ± 1.3 events
s−1; n = 9, P = 0.2, paired t test).
Most electrophysiological recordings so far were carried
out on late juvenile rats, on average aged around P20. Be-
cause we cannot exclude that developmental changes may
interfere with effects of IFN-γ, we firstly used linear regres-
sion analysis on age and effect size for all electrophysio-
logical experiments but found no correlation (probability;
Pearson correlation coefficient): input resistance (p 0.69; r
0.15), rheobase (0.64; − 0.18), F-I slope (0.99; − 0.002),
hyperpolarization-induced current amplitude (0.11; − 0.41),
evoked IPSC amplitude (0.39; 0.44), spontaneous IPSC
amplitude (0.92; 0.03), and miniature IPSC amplitude (0.22;
0.43). Secondly, because the inhibitory circuitry develops ra-
ther slow, rendering GABAergic transmission development
susceptible to extrinsic influences [35], we investigated
whether the synaptic effect of IFN-γ persists in adult rats.
In detail, we recorded sIPSCs at P60 and found—similar to
juvenile rats—an amplitude increase of sIPSCs by 15.7%
(from ctrl 45.4 ± 4.4 pA to IFN-γ 52.2 ± 5.2 pA; n = 8, P <
0.05, paired t test) while frequencies remained comparable
(ctrl 42.1 ± 9.2 events s−1 vs. IFN-γ 48.7 ± 12.6 events s−1;
n = 8, P = 0.18, paired t test, Fig. 5d–f). Here, the amplitude
of the largest (≥ 60 pA) sIPSCs increased by 11.8% (from
ctrl 88.8 ± 3.3 pA to IFN-γ 99.3 ± 5.3 pA; n = 8, P < 0.05,
paired t test) whereas their frequency remained unchanged
(ctrl 12.1 ± 4.3 events s−1 vs. IFN-γ 18.4 ± 7.1 events s−1;
n = 8, P = 0.07, paired t test).
Finally, we recorded miniature IPSCs (mIPSCs) in the
presence of glutamate receptor blockers and TTX to
analyze the effects of IFN-γ on inhibitory transmission,
while excluding any action potential driven responses.
After 20 min of application, IFN-γ increased the ampli-
tude of mIPSCs by 20% from ctrl 13.8 ± 1.2 pA to IFN-γ
16.5 ± 1.5 pA (n = 10; P < 0.01, paired t test) without any
Fig. 3 Ih is inhibited by IFN-γ in neocortical layer 5 neurons. a After 10 min, 1000 IU ml−1 IFN-γ decreased maximum amplitude of Ih and slowed
its activation and deactivation as exemplified by traces of pharmacologically isolated and offline leak subtracted Ih before (black) and upon (red)
direct IFN-γ application. Ih was elicited by the voltage step shown at the bottom. b IFN-γ reduced the Ih amplitude in all investigated neurons. c
For the graph steady-state activation, curves were constructed from average relative tail currents (SEM given as bars) upon returning to − 65mV
from Ih activation, plotted against preceding activating voltages before (black) and after the application of IFN-γ (red). Fits of Boltzmann function
are superimposed. Note that V1/2 after IFN-γ is depolarized and cannot explain the decrease in maximum Ih. d Application of IFN-γ decelerated
the fast component of activation (quantified by an increase of τfast, left) and Ih deactivation as indicated by increased deactivation times (right). Rs
remained constant (Rs-ctrl 9.7 ± 0.7 MΩ vs. Rs-IFN-γ 10.0 ± 0.7 MΩ, n = 16; P = 0.3, paired t test) throughout the experiments. Average age of animals
for this series of experiments P35.6 ± 11.0
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effect on the frequency (ctrl 8.2 ± 1.0 events s−1 vs. IFN-
γ 8.7 ± 1.7 events s−1; n = 10, P = 0.85, Wilcoxon signed-
rank test; Fig. 6a–c). Kinetic analysis of the 10% biggest
amplitudes indicated no changes of the decay time
(Fig. 6d, e).
These results provide evidence for an acute augmenta-
tion of GABAergic transmission by IFN-γ.
Discussion
Our main finding is that short-term IFN-γ application
provokes complex changes in neuronal function of
neocortical layer 5 pyramidal neurons, enabled by the
presence of type II IFN receptors on these neurons. In
detail, IFN-γ, when acutely released, augments inhibitory
currents in neocortical layer 5 pyramidal neurons. Aug-
mented perisomatic inhibition links our seemingly
conflicting other findings: on the one hand, the decrease
and slowing of Ih mimics the effect we previously found
for type I IFNs [22], which indicates a comparable, PKC-
mediated mechanism [21]. On the other hand, the therefore
expected increase in neuronal sub- and suprathreshold
excitability (as seen in the majority of neurons upon type I
IFNs [20]) was entirely absent.
Our newly found short-term effects of IFN-γ on
GABAergic responses in neocortical pyramidal neurons
in acute slice preparations add to the knowledge on
Fig. 4 IFN-γ increases the amplitude of evoked IPSCs in neocortical
layer 5 pyramidal neurons. Electrically evoked IPSCs were recorded
in the presence of CNQX and DAP5 to block ionotropic glutamate
receptors. a Exemplary layer 5 pyramidal neuron stained with
biocytin and reconstructed to ensure neuronal identity when
electrophysiological characterization was impaired by recording
conditions. Soma and dendrites are represented in black, the axon
in blue. b Example traces of IPSCs evoked before (gray) and after 30
min of IFNγ application (1000 IU ml−1; rose). Averaged traces are
shown in black (before IFN-γ application) and red (after IFN-γ
application). A scheme of the experimental setup, including the
apicolaterally positioned bipolar stimulation electrode, is depicted
below. c Maximum amplitudes of all eIPSCs increased under the
influence of IFN-γ. Analysis of eIPSC amplitudes was performed
before and 20 to 40 min after the application of IFN-γ. Holding
current (507.9 ± 189.0 pA vs. 1285.9 ± 626.0 pA, n = 6; P = 0.22,
Wilcoxon signed-rank test) and Rs (Rs-ctrl = 9.2 ± 2.1 MΩ vs. Rs-IFN-γ =
9.4 ± 2.2 MΩ, n = 6; P = 0.7, Wilcoxon signed-rank test) remained
comparable. Average rat age P23.7 ± 0.8
Fig. 5 IFN-γ increases the amplitude of spontaneous IPSCs in
neocortical layer 5 pyramidal neurons of late juvenile and adult rats.
Spontaneous IPSCs were recorded in the presence of CNQX and
DAP5 to block ionotropic glutamate receptors. a, d Example traces
of sIPSCs of late juvenile (a) and adult (d) rats before (black) and
after application of IFN-γ (1000 IU ml−1; 20 min; red). b, e IFN-γ
application (20 to 30 min) increased sIPSC amplitudes of pyramidal
neurons of late juvenile (b) and adult (e) rats (left) but left sIPSC
frequency (right) unchanged. c, f Cumulative sIPSC amplitudes in
neurons of late juvenile (c) and adult (f) rats after application of IFN-
γ (red) were shifted to bigger amplitudes when compared with
control (black). Holding current (for late juvenile rats 325.7 ± 91.9 pA
vs. 412.5 ± 72.5 pA, n = 9; P = 0.13, Wilcoxon signed-rank test/for
adult rats 135.5 ± 28.2 pA vs. 135.0 ± 19.5 pA, n = 8; P = 0.97, paired t
test) and Rs (for late juvenile rats Rs-ctrl = 9.2 ± 2.1 MΩ vs. Rs-IFN-γ =
9.4 ± 2.2 MΩ, n = 9; P = 0.7, Wilcoxon signed-rank test/for adult rats
Rs-ctrl = 7.1 ± 1.0 MΩ vs. Rs-IFN-γ = 7.0 ± 0.5 MΩ, n = 8; P = 0.8, paired t
test) remained comparable. Mean age of animals P19.0 ± 1.0 (late
juvenile) and P60.0 ± 0.6 (adult)
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long-term IFN-γ effects on inhibition. In line with our
findings of an augmented inhibition, layer 1 interneu-
rons respond to meningeal IFN-γ release and increase
tonic inhibition in layer 2 projection neurons [36]. Fur-
ther support of our findings comes from other brain re-
gions such as the hippocampus, where IFN-γ augmented
synaptic inhibition as shown in the brain slices of late ju-
venile rats by an increase in frequency of spontaneous and
miniature IPSCs [37] or in culture at peak synaptogenesis
by increased spontaneous IPSC frequency and miniature
IPSC amplitude [23], both at later time points, i.e., at hours
to days after IFN-γ exposure. The latter authors linked
their findings to increased neuronal activity, an interaction
that recently has been deciphered [38]. Such a mechanism
is not likely to account for our findings because we blocked
glutamatergic transmission with CNQX for AMPA and
DAP-5 for NMDA receptors in our experiments. However,
in contrast to these rather supporting findings on IFN-γ-
induced augmentation, there is also evidence for an attenu-
ation of inhibition. IFN-γ reduced or even depolarized
GABAergic activity in neurons in the dorsal horn of the
spinal cord [39] and increased IFN-γ levels diminished
inhibition by reducing frequency but not amplitude of
spontaneous and miniature inhibitory postsynaptic current
(IPSC) [40] in hippocampal CA1 neurons. Adding another
layer of complexity, the IFN-γ-induced reduction in GABA
release has been shown to increase hippocampal excitabil-
ity [40, 41], and IFN-γ may induce increase in hippocampal
excitatory synaptic activity and AMPA receptor clustering
without obvious changes in GABAergic transmission [25].
These inconsistent findings in diverse regions of the central
nervous system certainly demand further studies of local-
ized and age-dependent neuronal IFN-γ effects.
Although the similarity of the effects of IFN-γ and type I
IFNs on Ih suggests a comparable mechanism of acute
action, i.e., PKC mediation, the obvious differences in
influencing neuronal excitability together with the diverse
effects of mere IFN-γ application in different preparations
and brain regions described previously provoke several
speculations. The most parsimonious hypotheses are (1)
subcellular receptor location: IFN-γ receptors may prefer-
entially interact with inhibitory GABAA receptors at the
soma of pyramidal neurons whereas type I IFN receptors
might rather modulate dendritic conductances. A partial
overlap may explain the lack of suprathreshold effects in a
small subset (14/39) of IFN-β treated pyramidal neurons
[20]. (2) Different subcellular PKC subtype or intracellular
PKC target distribution [42]. (3) Differential action on
resident interneuron subclasses, depending on their ion
channel composition. (4) IFNs as cytokines rarely act
alone; thus, effects should be considered in conjunction
with other cytokines present or even induced in the local
environment. For instance, IFN-γ may evoke either TNFα
production in glial cells that, in turn, could influence
(excitatory) synaptic function [43] or CX3CL1 [44, 45].
Interestingly, the latter mimics the here described IFN-γ
effect, i.e., it augmented sIPSC amplitudes but not fre-
quencies when acutely applied [46]. However, this effect
was specific for serotonergic neurons, and CX3CL1 induc-
tion by IFN-γ was not described to be in the time frame of
Fig. 6 IFN-γ increases mIPSC amplitudes in neocortical layer 5
neurons. a Example traces of mIPSCs recorded in the presence of
CNQX, DAP5, and TTX before (black) and upon application of IFN-γ
(1000 IU ml−1; 20 min; red). b Mean mIPSC amplitudes (left) increased
upon application of IFN-γ, while mIPSC frequency (right) remained
unaltered. c Cumulative relative frequency graph of mIPSC
amplitudes for an example neuron shows an increase in amplitudes
after application of IFN-γ (red) in comparison to the initial state
(black). d Example trace of a single mIPSC before (black) and upon
application of IFN-γ (red). e IFN-γ did not influence mIPSC decay
time. Rs remained constant (Rs-ctrl 14.1 ± 0.7 MΩ vs. Rs-IFN-γ 14.5 ± 0.8
MΩ; n = 10; P = 0.55, paired t test) throughout the experiments.
Average rat age P16.1 ± 1.9
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the effects we observe, yet. (5) Finally, although our (spe-
cifically due to the time course) and several other studies
are in favor of a direct neuromodulatory effect of cyto-
kines, we cannot entirely exclude the possibility that a
variable (micro-)glial influence affects short- or long-term
neuromodulation [47], in particular, because IFN-γ in-
duced CX3CL1 release [44, 45] that might have an impact
on GABAergic networks, at least in development [48].
Our experiments suggest that early enhancement of
GABAergic inhibition may protect against pro-excitatory
events, as previously proposed by [36]. However, further
studies are needed here because the significance of the
results beyond the level of the brain slice still needs to be
clarified. Pro- and anti-excitatory incidents might be simul-
taneously induced by IFN-γ as HCN1 reduction has been
shown to be sufficiently counteracted by GABAergic en-
hancement [34]. Dampening neuronal activity might even
counteract the morphological changes indicative for up-
coming degeneration as dendritic beads initiated by Ca2+
permeable receptor complexes of IFN-γR and GluR1 [24]
or be beneficial before IFN-γ forces neurons to instruct in-
hibitory synapse loss in viral déjà vu disease [11]. Although
our experiments in acute brain slices do not provide data
on chronic impact, initial augmentation of GABAergic in-
hibition might lead to a rearrangement that finally results
in the chronic outcomes described by others (see above).
Whatever the exact mechanisms are, our finding might
show the onset of the suggested neuroprotective role. This
would be in line with findings that GABAergic activity was
enhanced in surviving neurons in primary cortical cultures
following rabies or influenza A infection [49, 50].
Recent research points to a role of IFN-γ (and therewith
putatively changes in inhibition) in the pathophysiology of
other diseases besides viral infections. IFN-γ was reported
to be involved in depressive behavior in humans [51], and
intraventricular delivery of IFN-γ caused a depressive and
anxiety-like behavior in mice due to dysfunction of the
cannabinoid receptor CB1Rs that (if functioning) reduces
GABA transmission in the striatum [52]. Our findings on
an altered synaptic transmission by IFN-γ add a new
aspect on the role of pro-inflammatory cytokines in epi-
lepsy. So far, IL-1β, TNFα, and IL-6 are regarded as major
pro-epileptic players [42]. In contrast, IFN-γ-induced aug-
mentation of inhibition might rather constrain seizures,
although its absence in development seems to diminish
seizures later in life [53].
Conclusion
The data improve our understanding of the role of IFN-γ
as a neuromodulatory cytokine [3] and reveal potential
mechanisms of altered behavior and perception during
early states of infectious diseases. Our data once more
emphasize that immune and nervous system do act au-
tonomously but mutually affect each other’s function.
Knowledge on IFN-γ-induced neuromodulation is import-
ant because it is of clinical relevance, due to IFN-γ pres-
ence in the CNS under pathological conditions and even
beyond, since it might influence social behavior [36].
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